LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to February 16, 2023.
About Prenetics
Founded in 2014, Prenetics is a major global diagnostic and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Consumer Health, Clinical Care and Medical & Cancer Genomics — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across nine locations, including The United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening and provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. Prenetics is listed on NASDAQ with the ticker PRE. To learn more about Prenetics, visit www.prenetics.com.
| Investor Relations Contact: | ||
| This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
| ICR Westwicke: | ||
| Caroline Corner | +415 202 5678 | Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Media contact: | ||
| Strategic Public Relations Group | ||
| Corinne Ho | +852 2114 4911 | Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$7.89 |
| Daily Change: | -0.32 -3.90 |
| Daily Volume: | 25,437 |
| Market Cap: | US$90.340M |
June 18, 2025 June 12, 2025 March 05, 2025 February 11, 2025 January 21, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
